Evidence map›Paper›PMID 40883334›Full record

ArticleScientific reports2025

Podoplanin expression is associated with local inflammation and survival in glioma.

Pegah Mir Seyed Nazari, Maximilian J Mair, Julia Riedl, Benedikt Schöllkopf, Florian Moik, Gerda Ricken, Georg Widhalm, Karin Dieckmann, Cihan Ay, Ingrid Pabinger and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pegah Mir Seyed NazariDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Maximilian J MairDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Julia RiedlDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Benedikt SchöllkopfDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Florian MoikDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Gerda RickenDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Georg WidhalmDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Karin DieckmannDepartment of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
Cihan AyDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Ingrid PabingerDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Matthias PreusserDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Anna Sophie BerghoffDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. anna.berghoff@meduniwien.ac.at.ORCID http://orcid.org/0000-0001-9379-6797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma subtypes differ in prognosis and treatment strategies. We aimed to determine the correlation of podoplanin (PDPN) expression in glioma subtypes with survival as well as systemic and local inflammation. In a prospective cohort study including 192 patients with glioma, tumor-infiltrating lymphocytes (TILs), programmed cell death ligand 1 (PD-L1) expression and podoplanin (PDPN) expression were analyzed by immunohistochemistry. PDPN and PD-L1 expression were more frequently observed in IDH1 wildtype (wt) compared to IDH1 mutant (mut) glioma (p = 0.015). In IDHwt glioma, overall survival was significantly longer in glioma patients without PDPN expression compared to those with PDPN expression (median 26.3 vs. 12.5 months, log-rank test, p < 0.001). Levels of tumor-infiltrating CD8 + and CD68 + cells were highest in IDH1wt glioma with both PDPN and PD-L1 expression (p < 0.001). IDH1wt, PDPN and non-PD-L1 expressing glioma presented with the highest neutrophil-to-lymphocyte (NLR) ratio in the blood compared to other subtypes (p = 0.023). Gliomas differ in the composition of the inflammatory microenvironment according to the presence of IDH1 mutation. Podoplanin, a marker of innate inflammation, is associated with survival prognosis and systemic inflammation in patients with IDH1wt glioma.

Indexed as

Brain NeoplasmsGliomaInflammationMembrane GlycoproteinsAdultAgedB7-H1 AntigenBiomarkers, TumorFemaleHumansIsocitrate DehydrogenaseLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationPodoplaninB7-H1 AntigenBiomarkers, TumorCD274 protein, humanIDH1 protein, humanIsocitrate DehydrogenaseMembrane GlycoproteinsPDPN protein, humanPodoplaninGliomaInflammatory subgroupsPD-L1PodoplaninSystemic inflammationTumor microenvironment

Identifiers

PMID40883334
PMCPMC12397430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.